As advised via Pharmac Tender announcement 31 May 2017, there is to be a change in the listing and future sole supply.

New listing HML from 1 January 2018

Ceftazidime Hospira Inj 1 g vial             Pharmacode  2245574                              Schedule price $2.20

Incumbent brand

Fortum Inj 1 g vial                                      Pharmacode  332941                                            Schedule price $1.55

Delisting HML 1 March 2018. (stocks are depleted)

Alternative temporary listing

Ceftazidime Mylan Inj 1 g 5 vial                         Pharmacode 2452294                   Schedule price $23.00

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author